Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by
rituximab maintenance therapy consisting of four weekly doses every six months for two years